Home › Alopecia › NCT07819435
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
RecruitingPhase 2/3
A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2/3 Study to Assess Efficacy and Long-Term Safety of PP405 in Adult Males With Androgenetic Alopecia
Who can join
Ages 18 to 55 · Men
Full eligibility criteria
Inclusion Criteria: 1. Males (assigned at birth) aged 18 to 55 years, inclusive at time of consent. 2. Able and willing to provide written informed consent 3. Must have been experiencing Androgenetic Alopecia (AGA) for at least 6 months prior to screening. 4. Have a modified Norwood-Hamilton score of Type IV or Type V 5. Agree to comply with protocol procedures Exclusion Criteria: 1. Concomitant diagnosis of non-AGA forms of alopecia. 2. Use of other hair loss treatments within periods specified in protocol. 3. Use of excluded medications and procedures as specified in protocol. 4. Diagnosis of other medical conditions as specified in protocol. 5. Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.
About the study
The study is designed to validate efficacy and long term safety of PP405.
What is being tested
- PP405 0.05% Topical Gel (drug)
- Vehicle Topical Gel (drug)
Sponsor: Pelage Pharmaceuticals, Inc. · Participants: 600 · Started: Sep 21, 2026
Contact the study team
- Lisa Sherman · Phone: 213-218-3830
Official record on ClinicalTrials.gov — NCT07819435
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.